Institution
Hebron University
Education•Hebron, Palestinian Territory•
About: Hebron University is a education organization based out in Hebron, Palestinian Territory. It is known for research contribution in the topics: Population & Cancer. The organization has 2714 authors who have published 4180 publications receiving 163736 citations.
Topics: Population, Cancer, Breast cancer, Medicine, Metastatic breast cancer
Papers published on a yearly basis
Papers
More filters
••
TL;DR: In this population of patients treated with entecvir after CHB‐related LT, entecavir was well tolerated and effective in maintaining viral suppression, even in individuals who experienced a reappearance of HBsAg.
45 citations
••
TL;DR: Although the authors' patients had more severe disease than those in the pivotal study, a similar reduction in ARR was observed, in line with previous observational studies, the effect was independent of baseline EDSS.
Abstract: Natalizumab has been shown to be effective in pivotal clinical trials in multiple sclerosis; however, the patients in whom treatment is indicated in clinical practice have a different clinical profile from those included in the clinical trials. The aim of this study is therefore to collect data on natalizumab use in everyday clinical practice in Spain. The 86 participating centers throughout Spain submitted data on disease characteristics at baseline and after treatment. Valid data were available for 1,364 patients (69.3% women, 86.9% with relapsing–remitting disease). Ninety-three percent had received prior therapy for multiple sclerosis. For the 825 patients on treatment for at least a year, the annualized relapse rate (ARR) decreased from median 2.0 [mean 2.01, 95% confidence interval (CI) 1.92–2.11] in the year prior to natalizumab to 0.0 (mean 0.25, 95% CI 0.21–0.29) at 1 year (p < 0.001). The Expanded Disability Status Scale (EDSS) score decreased from median 3.5 at baseline (mean 3.71, 95% CI 3.60–3.82) to 3.0 (mean 3.37, 95% CI 3.25–3.49) (p < 0.0001). The discontinuation rate was 14%. One patient discontinued natalizumab due to progressive multifocal leukoencephalopathy (PML) and another due to probable PML (subsequently confirmed). Although our patients had more severe disease than those in the pivotal study, a similar reduction in ARR was observed. This finding is in line with previous observational studies. The effect was independent of baseline EDSS.
45 citations
••
TL;DR: This study, which is the largest conducted to date in a South American population, provides a comprehensive analysis on the type and distribution of BRCA1/2 mutations and allelic variants.
Abstract: The distribution of BRCA1/2 germline mutations in breast/ovarian cancer (BC/OC) families varies among different populations. In the Chilean population, there are only two reports of mutation analysis of BRCA1/2, and these included a low number of BC and/or OC patients. Moreover, the prevalence of BRCA1/2 genomic rearrangements in Chilean and in other South American populations is unknown. In this article, we present the mutation-detection data corresponding to a set of 326 high-risk families analyzed by conformation-sensitive gel electrophoresis and heteroduplex analysis. To determine the contribution of BRCA1/2 LGRs in Chilean BC patients, we analyzed 56 high-risk subjects with no pathogenic BRCA1/2 point mutations. Germline BRCA1/2 point mutations were found in 23 (7.1%) of the 326 Chilean families. Families which had at least three BC and/or OC cases showed the highest frequency of mutations (15.9%). We identified 14 point pathogenic mutations. Three recurrent mutations in BRCA1 (c.187_188delAG, c.2605_2606delTT, and c.3450_3453delCAAG) and three in BRCA2 (c.4969_4970insTG, c.5374_5377delTATG, and c.6503_6504delTT) contributed to 63.6 and 66.7% of all the deleterious mutations of each gene, which may reflect the presence of region-specific founder effects. Taken together BRCA1/2 recurrent point mutations account for 65.2% (15/23) of the BRCA1/2 (+) families. No large deletions or duplications involving BRCA1/2 were identified in a subgroup of 56 index cases negative for BRCA1/2 point mutations. Our study, which is the largest conducted to date in a South American population, provides a comprehensive analysis on the type and distribution of BRCA1/2 mutations and allelic variants.
45 citations
••
German Cancer Research Center1, University of Leicester2, University of Santiago de Compostela3, University of Montpellier4, French Institute of Health and Medical Research5, Ghent University6, Manchester Academic Health Science Centre7, University of Cambridge8, Memorial Sloan Kettering Cancer Center9, Hebron University10, University of Manchester11, Icahn School of Medicine at Mount Sinai12, Katholieke Universiteit Leuven13, Maastricht University14, Heidelberg University15, University of Milan16, Ghent University Hospital17, National Council of Resistance of Iran18, University of Hamburg19, University Hospitals of Leicester NHS Trust20, Telford21, Nottingham University Hospitals NHS Trust22, Coventry Health Care23, Queen Elizabeth Hospital Birmingham24, Blackpool Victoria Hospital25, The Queen's Medical Center26
TL;DR: The comprehensive centralised database and linked biobank is a valuable resource for the radiotherapy community for validating predictive models and biomarkers and will also enable a better understanding of how many people suffer with radiotherapy toxicity.
45 citations
••
École Polytechnique de Montréal1, Université de Montréal2, University of Queensland3, University of British Columbia4, Harvard University5, Massachusetts Institute of Technology6, UCL Institute of Neurology7, University of Hamburg8, Medical College of Wisconsin9, Aix-Marseille University10, Vanderbilt University11, Université de Sherbrooke12, University of Strasbourg13, Masaryk University14, McGill University15, Max Planck Society16, Stanford University17, University of Zurich18, Juntendo University19, University of Pavia20, University College London21, Philips22, University of Minnesota23, Central European Institute of Technology24, Toho University25, University of Tokyo26, Northwestern University27, University of Birmingham28, Icahn School of Medicine at Mount Sinai29, University of Geneva30, École Polytechnique Fédérale de Lausanne31, Dresden University of Technology32, Chinese Academy of Sciences33, University of Oxford34, Epilepsy Society35, Cardiff University36, Capital Medical University37, University of Barcelona38, University of California, San Francisco39, Hebron University40, Open University of Catalonia41, University of Oklahoma42, Leipzig University43, University of Chieti-Pescara44
TL;DR: The spine generic protocol as mentioned in this paper provides guidance for assessing SC macrostructural and microstructural integrity: T1-weighted and T2-weighting imaging for SC crosssectional area computation, multi-echo gradient echo for gray matter cross-sectional area, and magnetization transfer and diffusion weighted imaging for assessing white matter microstructure.
Abstract: Quantitative spinal cord (SC) magnetic resonance imaging (MRI) presents many challenges, including a lack of standardized imaging protocols. Here we present a prospectively harmonized quantitative MRI protocol, which we refer to as the spine generic protocol, for users of 3T MRI systems from the three main manufacturers: GE, Philips and Siemens. The protocol provides guidance for assessing SC macrostructural and microstructural integrity: T1-weighted and T2-weighted imaging for SC cross-sectional area computation, multi-echo gradient echo for gray matter cross-sectional area, and magnetization transfer and diffusion weighted imaging for assessing white matter microstructure. In a companion paper from the same authors, the spine generic protocol was used to acquire data across 42 centers in 260 healthy subjects. The key details of the spine generic protocol are also available in an open-access document that can be found at https://github.com/spine-generic/protocols . The protocol will serve as a starting point for researchers and clinicians implementing new SC imaging initiatives so that, in the future, inclusion of the SC in neuroimaging protocols will be more common. The protocol could be implemented by any trained MR technician or by a researcher/clinician familiar with MRI acquisition.
45 citations
Authors
Showing all 2723 results
Name | H-index | Papers | Citations |
---|---|---|---|
José Baselga | 156 | 707 | 122498 |
M. I. Martínez | 134 | 1251 | 79885 |
Josep Tabernero | 111 | 803 | 68982 |
Jordi Rello | 103 | 694 | 35994 |
Xavier Montalban | 95 | 762 | 52842 |
James M. Downey | 91 | 381 | 29506 |
Enriqueta Felip | 83 | 622 | 53364 |
Joaquim Bellmunt | 82 | 660 | 41472 |
Joan Montaner | 80 | 489 | 22413 |
Marc Miravitlles | 76 | 651 | 25671 |
David H. Salat | 75 | 241 | 36779 |
Eduard Gratacós | 75 | 531 | 20178 |
Alex Rovira | 74 | 356 | 19586 |
Ramon Bataller | 72 | 283 | 19316 |
Maria Buti | 71 | 493 | 26596 |